Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some core mechanistic and dosing elements align with the COSENTYX label excerpts (e.g., IL-17A binding/inhibition of receptor interaction; psoriasis 300 mg loading schedule and AS consideration of 300 mg if persistent). However, many efficacy-burden-personalization claims and several safety/interaction/monitoring statements are unsupported or overgeneralized relative to the provided label text, and multiple claims assert dose-escalation broadly without the label’s condition-specific context.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A).
11 DESCRIPTION; 12.1 Mechanism of Action
Cosentyx works by binding to IL-17A, preventing it from interacting with its receptor on the surface of immune cells.
12.1 Mechanism of Action (inhibits interaction with IL-17 receptor)
For psoriasis, the typical dosage regimen for Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
2.3 Recommended Dosage in Plaque Psoriasis (300 mg subcutaneously at Weeks 0-4 and every 4 weeks thereafter)
For ankylosing spondylitis, the typical dosage regimen for Cosentyx is 150 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.
2.6 Recommended Dosage in Adults with Ankylosing Spondylitis (150 mg subcutaneous; with or without loading; consider increasing to 300 mg every 4 weeks if active persists). Note: the label excerpt does not explicitly state the 150 mg every-4-weeks maintenance schedule with the same Week 0-4 phrasing for AS in the provided text.
Increasing the dosage of Cosentyx can lead to improved efficacy in patients with psoriasis.
2.3 Recommended Dosage in Plaque Psoriasis (label notes 150 mg for some patients; implies dose selection by some patients, but does not explicitly state “increasing dose improves efficacy” in the provided excerpt).
Unsupported Statements
By blocking IL-17A, Cosentyx reduces inflammation and slows the growth of skin cells, leading to improved symptoms in patients with psoriasis.
Mechanism is supported, but the provided excerpts do not state the specific downstream claims (slows skin cell growth) or link IL-17A blockade to these specific outcomes for psoriasis.
Preventing IL-17A receptor interaction reduces inflammation and slows skin cell growth, resulting in improved symptoms in patients with psoriasis.
Same issue: label excerpt supports IL-17A receptor interaction inhibition, but does not support the specific “slows skin cell growth” and symptom phrasing.
A study found that patients who received a higher dosage of Cosentyx (600 mg) had improved efficacy compared to those who received the standard dosage (300 mg).
No 600 mg psoriasis/label dosing or efficacy comparison is present in the provided label excerpts.
Increasing the dosage of Cosentyx can lead to increased side effects, such as injection site reactions and upper respiratory tract infections.
The label excerpt provided discusses infections and dose-dependent fungal infections, and mentions adverse reactions generally, but it does not provide the specific claim that higher dose increases injection site reactions or upper respiratory tract infections.
Adjusting the dosage of Cosentyx can reduce treatment burden for patients, making it easier to adhere to treatment.
The provided label excerpts do not discuss treatment burden, adherence, or convenience as dosing rationale.
Adjusting Cosentyx can be tailored to individual patient needs, allowing for more personalized treatment.
The label excerpt supports dose options (e.g., 150 mg vs 300 mg for some patients; consider increasing for persistent disease), but it does not support the broader “personalized treatment” framing.
Adjusting Cosentyx can interact with other medications, such as immunosuppressants and biologics.
The label excerpt only provides a general interaction concept regarding CYP450 substrate monitoring; it does not specifically mention immunosuppressants or biologics or any interaction related to dose adjustment.
Patient characteristics (including age, sex, and body mass index) can influence the efficacy of Cosentyx.
The provided label excerpts do not state that age/sex/BMI influence efficacy.
Disease severity can influence the efficacy of Cosentyx.
Not supported in the provided label excerpts.
Comorbidities (such as diabetes and hypertension) can influence the efficacy of Cosentyx.
Not supported in the provided label excerpts.
Regularly monitoring treatment response can help identify patients who may benefit from dosage adjustments.
The provided label excerpts do not describe monitoring treatment response for identifying patients for dose adjustment.
Adjusting the dosage of Cosentyx can help improve efficacy and reduce treatment burden.
Label excerpts do not address treatment burden/adherence or directly support this combined claim.
Combining Cosentyx with other treatments, such as topical corticosteroids and phototherapy, can help improve efficacy.
The provided label excerpt does not discuss combination efficacy with topical corticosteroids or phototherapy.
Adjusting Cosentyx can reduce treatment burden and improve adherence to treatment.
Not supported by provided label excerpts.
Patients and healthcare providers can optimize Cosentyx treatment by monitoring treatment response, adjusting dosage, and combining with other treatments.
Not supported: the label excerpts provided do not describe these optimization/adherence concepts or combination specifics.
Adjusting Cosentyx can improve efficacy, reduce treatment burden, and improve adherence to treatment.
Not supported by provided label excerpts for burden/adherence.
Adjusting Cosentyx can lead to increased side effects, interactions with other medications, and reduced efficacy.
The label excerpts support infections/hypersensitivity risk and a general CYP450 monitoring concept, but do not support the specific claim that adjusting Cosentyx leads to reduced efficacy or that interactions specifically increase due to adjustment.
Adjusting Cosentyx can reduce treatment burden and improve adherence to treatment.
No label support in provided excerpts.
Adjusting the dosage of Cosentyx can be tailored to individual patient needs, allowing for more personalized treatment.
Broader phrasing not supported; only condition-specific dose considerations are present in provided excerpts.
Contradictions
Important Omissions
Boxed warning (if any) / or explicit statement that there is no boxed warning. The AI response does not address boxed warnings.
Importance:
Low
Label-required pre-treatment and ongoing evaluations (TB evaluation; vaccinations; monitoring for infections and IBD; avoid live vaccines). The AI response discusses monitoring response but not these label-specific safety procedures.
Importance:
Moderate
Specific contraindication (serious hypersensitivity to secukinumab/excipients). The AI response does not mention contraindications.
Importance:
Moderate
Administration instructions and limitations (subcutaneous-only for pens/syringes; solution in vials is IV in adults only; pediatric self-administration restrictions). The AI response provides dosing but no administration restrictions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While dosing schedules for psoriasis 300 mg align, the response includes multiple unsupported or overbroad claims about efficacy with higher dosing (e.g., 600 mg), dose adjustment reducing burden/adherence, and specific side effect and interaction statements. It also omits key label safety elements (TB screening, vaccination guidance, live vaccine avoidance, monitoring/discontinuation for serious infection).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported or too specific (e.g., 600 mg efficacy study; specific side effects and interactions; BMI/diabetes/HTN influence) and key label-required safety/administration information is omitted.
Suggested Improvement
Restrict efficacy and safety/dosing-change statements to what the provided label excerpts support (e.g., IL-17A mechanism; label dose schedules; condition-specific “consider increasing” language) and add label-specific safety steps (TB evaluation; vaccinations/live vaccine avoidance; infection/IBD monitoring; hypersensitivity discontinuation) and administration limitations for subcutaneous vs IV and pediatric self-administration.